Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pancreatic kininogenase is an enzyme preparation extracted from pig pancreas tissue that acts as a vasodilator and improves microcirculation. It promotes the release of kinins, which enhance blood vessel dilation, improve microcirculation, regulate blood pressure, prevent thrombosis and basement membrane thickening. It is mainly used to treat microcirculation disorders such as diabetic nephropathy, retinopathy, peripheral neuropathy, fundus disease, ischemic cerebrovascular disease and can be used adjunctively for hypertension. Pancreatic kininogenase has shown efficacy in ameliorating renal fibrosis in diabetic nephropathy by inhibiting transforming growth factor-β1 (TGF-β1) expression and modulating miR-433 and antizyme inhibitor 1 (Azin1). It also has therapeutic effects on diabetic peripheral neuropathy comparable to prostaglandin E1 but at a lower cost. The drug is administered orally as an enteric-coated tablet to protect it from stomach acid degradation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pancreatic kininogenase.